Sovereign Capital exits consultancy Xendo to ProPharma Group
Sovereign Capital Partners has exited pharmaceutical consultancy Xendo to ProPharma Group, a portfolio company of US-based Linden Capital Partners.
The
Sovereign Capital Partners has exited pharmaceutical consultancy Xendo to ProPharma Group, a portfolio company of US-based Linden Capital Partners.
The